指南与共识毛发、甲与色素性疾病

国际专家与色素性疾病学会关于黄褐斑管理的德尔菲共识

Delphi consensus on melasma management by international experts and pigmentary disorders society.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2025-09-25

该共识由色素性疾病学会组织11个国家38名皮肤科医生,采用改良德尔菲法经三轮调查制定,并检索2014至2024年文献按牛津证据等级分级。共识强调广谱防晒为必需,氢醌三联乳膏为金标准但需监管使用,并列出外用壬二酸、曲酸及口服氨甲环酸等替代方案。

要点

  • 广谱防晒是黄褐斑管理的基础,所有患者均应每日使用。
  • 氢醌三联乳膏为金标准,但须在医生监管下使用。
  • 化学换肤和微针可辅助外用治疗,激光仅用于难治性病例。

核心结论

  • 共识推荐整合专家意见与循证策略以改善全球黄褐斑患者结局。
  • 未来研究应聚焦新兴疗法评估与长期维持策略优化。

研究设计与样本

  • 采用改良德尔菲法,由2名资深色素性疾病专家核心组指导。
  • 38名来自11个国家的皮肤科医生参与三轮调查与讨论。
  • 文献检索2014至2024年文章,按牛津证据等级(2009)分级。
  • 采用5点Likert量表评估,预设高(≥75%)、中(55%-74%)、低(<55%)一致阈值。

主要发现

  • 初始34条陈述,第三轮后分别有21条、4条和1条达到高、中、低一致。
  • 关键推荐包括广谱防晒为必需、氢醌三联乳膏为金标准。
  • 替代方案包括外用壬二酸、曲酸和口服氨甲环酸。
  • 化学换肤和微针建议用于增强外用疗效,激光保留给难治性病例。

关键数值与推荐

  • 高一致阈值≥75%,中一致55%-74%,低一致<55%。
  • 氢醌三联乳膏为金标准,需规范与监管使用。
  • 广谱防晒为必需措施。
  • 激光仅用于难治性病例。

临床怎么用

  • 所有黄褐斑患者应每日使用广谱防晒。
  • 氢醌三联乳膏应在医生监管下使用。
  • 可选用壬二酸、曲酸或口服氨甲环酸作为替代。
  • 化学换肤和微针可作为辅助治疗增强外用疗效。
  • 激光治疗应保留给对其它治疗无反应的患者。

局限性

  • 共识基于专家意见与文献综合,非系统评价。
  • 需进一步研究评估新兴疗法与长期维持策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melasma, an acquired hyperpigmentation disorder, affects individuals of all ethnicities. Its multifactorial aetiology, high recurrence rates and psychosocial impact complicate management and necessitate comprehensive, evidence-based recommendations. OBJECTIVES: The objective was to develop an international consensus on the diagnosis and management of melasma by synthesizing expert opinions and the latest scientific evidence. METHODS: This consensus was developed using a modified Delphi approach. A core group of two senior dermatologists who were experts in pigmentary disorders guided the process, and a diverse panel of 38 dermatologists with a special interest in pigmentary disorders from 11 countries (Australia, Brazil, France, India, Italy, Mexico, Philippines, South Africa, South Korea, Taiwan and the USA) participated in three rounds of surveys and discussions, under the aegis of the Pigmentary Disorders Society (PDS). A literature search of articles published between 2014 and 2024 identified key studies that were graded using the Oxford levels of evidence (2009). Consensus statements were drafted, refined and finalized based on expert feedback. Responses were assessed using a 5-point Likert scale, with predefined thresholds for high (≥75%), moderate (55%-74%) and low (<55%) agreement. RESULTS: The consensus development process started with 34 statements, and at the end of the third round of the Delphi process, 21, 4 and 1 statement reached high, moderate and low consensus, respectively. Key recommendations highlighted photoprotection with broad-spectrum sunscreens as essential, regulated and supervised use of hydroquinone-based triple combination creams as the gold standard, and alternatives such as topical azelaic acid, kojic acid and oral tranexamic acid. Adjunctive procedural therapies, such as chemical peels and microneedling, were suggested to enhance topical efficacy, while lasers were reserved for refractory cases. CONCLUSIONS: These recommendations aim to improve the outcomes of melasma patients globally by integrating expert opinion and evidence-based strategies. Future research should focus on evaluating emerging therapies and optimizing long-term maintenance strategies. Melasma is a common skin condition that causes dark patches on the face. It affects people of all skin types and can have a major impact on confidence and quality of life. Treating melasma is challenging because it has many causes, tends to come back after treatment, and often requires a long‐term plan. To help improve care, a group of international experts worked together with the Pigmentary Disorders Society (PDS) to develop clear recommendations for how to diagnose and manage melasma. The group included 40 dermatologists from 11 countries, and their advice was based on both published research and their clinical experience. The recommendations were created using a structured process to reach agreement on best practices. The experts agreed that daily sun protection with broad‐spectrum sunscreen is essential for everyone with melasma. The most effective treatment remains hydroquinone‐based triple combination creams, but these should only be used under medical supervision. Other options include topical agents such as azelaic acid and kojic acid, as well as oral tranexamic acid. Procedures like chemical peels and microneedling can be used alongside creams to improve results, while lasers should mainly be considered for patients who do not respond to other treatments. These international recommendations aim to help doctors provide more effective and consistent care for patients with melasma around the world. Further studies are needed to better understand new treatments and strategies for preventing relapses.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Sarkar R, Desai SR, Sinha S, et al. Delphi consensus on melasma management by international experts and pigmentary disorders society. J Eur Acad Dermatol Venereol. 2025. PMID: 40996222. doi:10.1111/jdv.70066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。